BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Simponi golimumab regulatory update

FDA issued a complete response letter for an sBLA from Johnson & Johnson to expand the label for Simponi golimumab to include inhibiting the progression of structural damage, inducing major clinical response, maintenance of reducing...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >